nanotech-investing Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel , an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies
nanotech-investing Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma
nanotech-investing Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma
nanotech-investing Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference
nanotech-investing Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update
nanotech-investing Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology Annual Meeting
nanotech-investing Caribou Biosciences to Host KOL Discussion with Webcast from the 2024 ASCO Annual Meeting and Participate in Upcoming Investor Conferences
nanotech-investing Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
